December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Cognitive function in the Age-Related Eye Disease Study (AREDS)
Author Affiliations & Notes
  • TE Clemons
    The EMMES Corporation Rockville MD
  • AS Lindblad
    The EMMES Corporation Rockville MD
  • WL McBee
    The EMMES Corporation Rockville MD
  • LD HubbardAREDS Research Group
    Fundus Photograph Reading Center University of Wisconsin Madison WI
  • Footnotes
    Commercial Relationships   T.E. Clemons, None; A.S. Lindblad, None; W.L. McBee, None; L.D. Hubbard, None. Grant Identification: NEI contract N01-EY-0-2127
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1906. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      TE Clemons, AS Lindblad, WL McBee, LD HubbardAREDS Research Group; Cognitive function in the Age-Related Eye Disease Study (AREDS) . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1906.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To investigate the correlation of age-related macular degeneration (AMD) and use of high-dose vitamin/mineral supplements with cognitive function and depression. Methods: AREDS participants were randomly assigned to receive daily tablets containing (1) antioxidants (vitamin C, vitamin E, and beta carotene); (2) zinc (zinc oxide) and copper (cupric oxide); (3) antioxidants plus zinc; or (4) placebo. The AREDS Cognitive Function Battery includes 6 validated neuropsychological tests measuring performance in several cognitive domains and a depression scale. Participants were classified into one of four AMD categories at the time of administration: (1) no drusen; (2) extensive small drusen or non-extensive intermediate drusen; (3) large drusen, extensive intermediate drusen, or non-central geographic atrophy; and (4) advanced AMD or vision loss due to AMD in at least one eye. Dunnett's multiple comparison test identified differences in means by AMD category and treatment. Cognitive impairment and depression, defined as falling below the 10th percentile of the AREDS population, was assessed using logistic regression. Results: The Battery was administered to 2,681 participants age 61-87 years. Mean scores for a majority of tests declined with age, and differed by race, gender and education level (P<0.05). After adjusting for these factors, participants with advanced AMD were relatively more depressed compared to those without AMD (Odds Ratio (OR)=1.92, 95% CI: 1.27-2.91). After additional adjustment for depression score, participants with advanced AMD compared to those without had a relatively lower Modified Mini Mental State Exam score (OR= 2.61, 95% CI: 1.66-4.10). ORs for the remaining tests were in the direction of risk but none were significant (OR range 1.05-1.40). A risk factor adjusted analysis including baseline AMD category and treatment duration found that zinc significantly reduced cognitive impairment compared to placebo for the Animal Categories Test (OR=0.60, 95%CI: 0.36-0.99). ORs for zinc and the other batteries were not significant (OR range 0.68-1.08). None of the ORs for the antioxidant alone (OR range 0.68-1.23) and antioxidant plus zinc (OR range 0.68-1.25) formulations was significant (OR range 0.68-1.28). Conclusion: These data suggest an association between lower scores on depression and cognitive function test and advanced AMD, but do not support an association between supplementation with antioxidants and/or zinc and cognitive function.

Keywords: 308 age-related macular degeneration • 536 quality of life 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.